Resmed Inc (ASX:RMD) Expands Sleep Therapy Portfolio Following Fiscal Results

Aditi Sarkar

20 October 2026 04:53 PM AEDT

Resmed Inc (ASX:RMD) Expands Sleep Therapy Portfolio Following Fiscal Results

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Resmed (ASX:RMD) launched its AirTouch F40 fabric CPAP mask in the United States in October 2026.
Fiscal 2026 revenue reached US$5.653 billion, according to the company’s annual results.
Fiscal 2026 net income totalled US$1.523 billion; operating cash flow was approximately US$1.8 billion.
The company scheduled its fiscal 2027 first-quarter earnings release for 29 October 2026.

Resmed Inc develops sleep and breathing health equipment, including cloud-connected positive airway pressure devices, masks and associated digital services, alongside software used in care delivered outside hospitals. The company recently introduced a new fabric CPAP mask in the United States and reported fiscal 2026 results covering the year ended 30 June. On 20 October 2026, Resmed Inc (ASX:RMD) was quoted at AUD 34.25, up 0.53% during the trading session. The product launch and the approaching quarterly earnings announcement provide current developments for assessing its operations.

Company Business

Resmed operates through Sleep and Breathing Health and Residential Care Software activities. Its respiratory portfolio includes CPAP, automatic positive airway pressure and ventilation devices, together with masks, accessories and connected patient-monitoring tools. The AirView platform supports clinical monitoring, while myAir helps patients track their treatment. The group serves markets in the Americas and internationally, with medical devices and recurring mask purchases contributing to sales. Residential Care Software supplies technology for providers working in home-based and other out-of-hospital care settings.

Recent Development

On 19 October 2026, Resmed (ASX:RMD) announced the United States launch of AirTouch F40, a full-face CPAP mask fitted with a fabric cushion. The launch broadens its fabric mask range for people receiving treatment for obstructive sleep apnea. Product fit, comfort and ongoing therapy use remain relevant clinical and commercial considerations, although the company did not assign a revenue contribution to the new mask. The launch follows the completion of Resmed’s acquisition of Noctrix Health in June 2026, adding a treatment offering within its sleep-health portfolio.

Resmed also announced in July 2026 an agreement to sell its MatrixCare business for approximately US$490 million in cash, subject to adjustments, approvals and customary conditions. The proposed transaction reflects a narrower focus on sleep, breathing and connected care activities. The announced transaction terms, rather than an assumed completion date, are the appropriate basis for monitoring any subsequent portfolio changes.

Financial Performance and Sector Context

For fiscal 2026, Resmed (ASX:RMD) reported revenue of US$5.653 billion, an increase of approximately 10% from the preceding fiscal year. Net income reached US$1.523 billion, while diluted earnings per share were US$10.43. Fourth-quarter revenue was approximately US$1.464 billion and quarterly net income was US$383.4 million. The company reported a full-year gross margin of 61.1% and operating income of approximately US$1.887 billion. These figures are reported in US dollars and relate to the financial year ended 30 June 2026.

Sleep and Breathing Health generated approximately US$4.978 billion in fiscal 2026 revenue, comprising US$3.281 billion in the Americas and US$1.697 billion elsewhere. Residential Care Software contributed approximately US$675.8 million. Full-year operating cash flow was about US$1.8 billion, while cash and equivalents stood near US$1.5 billion at year-end. Resmed reported increased device and mask sales, with currency movements also affecting international comparisons. Market access, reimbursement arrangements, product regulation and patient treatment adherence influence the broader respiratory-device industry.

Risks to Consider

Resmed (ASX:RMD) faces manufacturing, supply-chain and product-quality requirements across regulated healthcare markets. Changes in reimbursement policy, competitive device offerings and foreign-exchange movements could affect reported outcomes. Integration of acquired businesses and the proposed MatrixCare disposal also involve execution and transition considerations. The October product introduction does not establish how quickly sales may develop or whether patients will adopt the mask at anticipated rates. Monitoring reported results is therefore more informative than assigning an unverified financial effect to the launch.

What to Watch Next

Resmed has scheduled a fiscal 2027 first-quarter earnings call for 29 October 2026. The accompanying financial release should provide an updated view of device demand, mask sales, geographic performance and operating expenses. For Resmed (ASX:RMD), investors can also monitor any announcement confirming the status of the MatrixCare transaction, further integration details relating to Noctrix Health and distribution of AirTouch F40. Material changes should be assessed using subsequent official company disclosures rather than extrapolation from a single product release.

Key Insights

Resmed (ASX:RMD) entered the new financial year following reported fiscal 2026 revenue of US$5.653 billion, net income of US$1.523 billion and operating cash flow of approximately US$1.8 billion. Its latest US mask introduction adds to an established portfolio of connected respiratory products. The next financial report, portfolio transaction updates and ongoing segment disclosures will clarify how these activities appear in subsequent results.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.